Rosalind Walley

1.5k total citations · 1 hit paper
19 papers, 1.1k citations indexed

About

Rosalind Walley is a scholar working on Statistics and Probability, Economics and Econometrics and Molecular Biology. According to data from OpenAlex, Rosalind Walley has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Statistics and Probability, 5 papers in Economics and Econometrics and 4 papers in Molecular Biology. Recurrent topics in Rosalind Walley's work include Statistical Methods in Clinical Trials (9 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Metabolomics and Mass Spectrometry Studies (3 papers). Rosalind Walley is often cited by papers focused on Statistical Methods in Clinical Trials (9 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Metabolomics and Mass Spectrometry Studies (3 papers). Rosalind Walley collaborates with scholars based in United Kingdom, United States and Belgium. Rosalind Walley's co-authors include Christopher J. Weir, G. Hanton, Jeremy R. Everett, John C. Lindon, Olivier Cloarec, Jeremy K. Nicholson, David Baker, Claude Charuel, T. Andrew Clayton and Jean-Loïc Le Net and has published in prestigious journals such as Nature, Journal of the American Society of Nephrology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Rosalind Walley

18 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmaco-metabonomic phenotyping and personalized drug treatment

2006 621 citations T. Andrew Clayton, John C. Lindon et al. Nature profile →

Peers

Rosalind Walley

PHARM

SPECT

Alexander Staab Germany

Thomas Kerbusch Netherlands

Rajanikanth Madabushi United States

Tomas Salmonson Sweden

Bengt Hamrén Sweden

Jane P. F. Bai United States

Kayode Ogungbenro United Kingdom

Hao Zhu United States

Wojciech Krzyżański United States

Jenny Y. Chien United States

Alexander Staab Germany

Rosalind Walley

445 ×0.8

156 ×0.8

175 ×1.3

PHARM

93 ×0.8

34 ×0.3

SPECT

Citations per year, relative to Rosalind Walley Rosalind Walley (= 1×) peers Alexander Staab

Countries citing papers authored by Rosalind Walley

Since Specialization

Citations

This map shows the geographic impact of Rosalind Walley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosalind Walley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosalind Walley more than expected).

Fields of papers citing papers by Rosalind Walley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosalind Walley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosalind Walley. The network helps show where Rosalind Walley may publish in the future.

Co-authorship network of co-authors of Rosalind Walley

This figure shows the co-authorship network connecting the top 25 collaborators of Rosalind Walley. A scholar is included among the top collaborators of Rosalind Walley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosalind Walley. Rosalind Walley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Walley, Rosalind, et al.. (2022). From innovative thinking to pharmaceutical industry implementation: Some success stories. Pharmaceutical Statistics. 21(4). 712–719.

Walley, Rosalind & Andrew P. Grieve. (2021). Optimising the trade‐off between type I andIIerror rates in the Bayesian context. Pharmaceutical Statistics. 20(4). 710–720. 10 indexed citations

Seifu, Yodit, et al.. (2020). Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review. Therapeutic Innovation & Regulatory Science. 54(6). 1436–1443. 11 indexed citations

Walley, Rosalind, et al.. (2019). Pooling Different Safety Data Sources: Impact of Combining Solicited and Spontaneous Reports on Signal Detection In Pharmacovigilance. Drug Safety. 42(10). 1191–1198. 12 indexed citations

Lim, Jessica, Li Wang, Nicky Best, et al.. (2019). Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias. Therapeutic Innovation & Regulatory Science. 54(4). 850–860. 13 indexed citations

Lim, Jessica, Rosalind Walley, Jiacheng Yuan, et al.. (2018). Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities. Therapeutic Innovation & Regulatory Science. 52(5). 546–559. 82 indexed citations

Scheele, Wim H., Susan M. Diamond, Jeremy D. Gale, et al.. (2016). Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy. Journal of the American Society of Nephrology. 27(11). 3459–3468. 53 indexed citations

Walley, Rosalind, et al.. (2016). Using Bayesian analysis in repeated preclinical in vivo studies for a more effective use of animals. Pharmaceutical Statistics. 15(3). 277–285. 9 indexed citations

Buchan, Peter, Hishani Kirby, J.A. Soranson, et al.. (2015). First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. 24(10). 1045–1056. 54 indexed citations

10.

Walley, Rosalind, Claire Smith, Jeremy D. Gale, & Phil Woodward. (2015). Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study. Pharmaceutical Statistics. 14(3). 205–215. 37 indexed citations

11.

Tytgat, D., et al.. (2015). Addressing potential prior‐data conflict when using informative priors in proof‐of‐concept studies. Pharmaceutical Statistics. 15(1). 28–36. 15 indexed citations

12.

Pullen, Nick, et al.. (2011). The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies. Human Reproduction Update. 17(6). 791–802. 32 indexed citations

13.

Howe, David, Natalie Mount, Amy Brown, et al.. (2011). The Translational Efficacy of a Nonsteroidal Progesterone Receptor Antagonist, 4-[3-Cyclopropyl-1-(mesylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy,-2,6-dimethylbenzonitrile (PF-02413873), on Endometrial Growth in Macaque and Human. Journal of Pharmacology and Experimental Therapeutics. 339(2). 642–653. 1 indexed citations

14.

Woodward, Phil & Rosalind Walley. (2009). Bayesian Variable Selection for Fractional Factorial Experiments with Multilevel Categorical Factors. Journal of Quality Technology. 41(3). 228–240. 3 indexed citations

15.

Walley, Rosalind, et al.. (2007). Designing Compound Subsets: Comparison of Random and Rational Approaches Using Statistical Simulation. Journal of Chemical Information and Modeling. 47(6). 2149–2158. 17 indexed citations

16.

Beckonert, Olaf, et al.. (2006). Gas chromatography/flame ionisation detection mass spectrometry for the detection of endogenous urine metabolites for metabonomic studies and its use as a complementary tool to nuclear magnetic resonance spectroscopy. Rapid Communications in Mass Spectrometry. 20(15). 2271–2280. 38 indexed citations

17.

Clayton, T. Andrew, John C. Lindon, Olivier Cloarec, et al.. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 440(7087). 1073–1077. 621 indexed citations breakdown →

18.

Weir, Christopher J. & Rosalind Walley. (2005). Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Statistics in Medicine. 25(2). 183–203. 125 indexed citations

19.

Hanton, G., et al.. (1993). Effects of hydrochlorothiazide and captopril on the survival and heart weight of cardiomyopathic hamsters.. PubMed. 81(2). 159–66. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact